Results 101 to 110 of about 4,767 (196)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Journal of Translational Medicine, 2019
Background Previous studies have identified IFNγ as an important early barrier to oncolytic viruses including vaccinia. The existing innate and adaptive immune barriers restricting oncolytic virotherapy, however, can be overcome using autologous or ...
Dobrin D. Draganov, Antonio F. Santidrian, Ivelina Minev, Duong Nguyen, Mehmet Okyay Kilinc, Ivan Petrov, Anna Vyalkova, Elliot Lander, Mark Berman, Boris Minev, Aladar A. Szalay   +10 more
doaj   +1 more source

Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9

Oncotarget, 2017
Oncolytic virotherapy is being developed as a promising platform for cancer therapy due to its ability to lyse cancer cells in a tumor-specific manner. Vaccinia virus has been used as a live vaccine in the smallpox eradication program and now is being potential in cancer therapy with a great safety profile. Vaccinia strain Guang9 (VG9) is an attenuated
Deng, Lili, Fan, Jun, Ding, Yuedi, Zhang, Jue, Zhou, Bin, Zhang, Yi, Huang, Biao   +6 more
openaire   +3 more sources

Experimental Study on Treatment of Gastric Cancer with New Recombinant Oncolytic Vaccinia Virus Infection Combined with Immune Effective Cells and Immune Checkpoint Blocking

Zhongliu Fangzhi Yanjiu
ObjectiveTo explore the significance of the combined strategy of oncolytic virus infection, immune effector cell supplement, and immune checkpoint blocking in the treatment of gastric cancer.
Lin ZHANG, Yanhong HOU, Kai WU, Jing ZHANG   +3 more
doaj   +1 more source

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine

Molecular Therapy: Oncolytics, 2017
Oncolytic viruses have proven their therapeutic potential against a variety of different tumor entities both in vitro and in vivo. Their ability to selectively infect and lyse tumor cells, while sparing healthy tissues, makes them favorable agents for ...
Eike Binz, Susanne Berchtold, Julia Beil, Martina Schell, Christine Geisler, Irina Smirnow, Ulrich M. Lauer   +6 more
doaj   +1 more source

Efficacy and safety of oncolytic vaccinia virus and Semliki Forest virus in the treatment of canine and feline malignant tumours

, 2015
Cancer is one of the most common reasons for death in dogs, cats and humans. New therapeutic modalities are necessary to improve disease outcome. One promising approach is oncolytic virotherapy. Until now, the only oncolytic virus evaluated in a clinical
Autio, Karoliina
core  

Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery

Frontiers in Oncology, 2017
Despite advances in technology, the formidable challenge of treating cancer, especially if advanced, still remains with no significant improvement in survival rates, even with the most common forms of cancer.
Dana Haddad
doaj   +1 more source

Novel Treatment of Colonic Dysplasia with an Oncolytic Vaccinia Virus

, 2013
Colonic dysplasia is a non-invasive intraepithelial neoplastic process that can eventually become cancer. Novel therapies are needed for dysplastic lesions not amenable to standard treatment.
Angarita, Fernando Andres
core   +1 more source

Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies

Cell Reports, 2016
The immune response plays a key role in enhancing the therapeutic activity of oncolytic virotherapies. However, to date, investigators have relied on inherent interactions between the virus and the immune system, often coupled to the expression of a ...
Juan J. Rojas, Padma Sampath, Braulio Bonilla, Alexandra Ashley, Weizhou Hou, Daniel Byrd, Steve H. Thorne   +6 more
doaj   +1 more source

Investigation of strategies to enhance the delivery of oncolytic vaccinia virus

, 2020
Vaccinia Virus (VV) is an attractive vector for oncolytic virotherapy given its potential for tumour-selective tropism, efficient cell-to-cell spread, rapid replication in cancer cells, large transgene coding capacity and stimulation of anti-tumour immunity.
openaire   +1 more source

Oncolytic properties of non-vaccinia poxviruses.

, 2018
International audienceVaccinia virus, a member of the Poxviridae family, has been extensively used as an oncolytic agent and has entered late stage clinical development.
Ricordel, Marine, Pichon, Christelle, Tosch, Caroline, Camus-Bouclainville, Christelle, Cochin, Sandrine, Findeli, Annie, Erbs, Philippe, Bertagnoli, Stéphane, Quéméneur, Eric, Foloppe, Johann, Cordier, Pascale   +10 more
core   +1 more source